James C. Yang

33.2k total citations · 11 hit papers
140 papers, 20.9k citations indexed

About

James C. Yang is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, James C. Yang has authored 140 papers receiving a total of 20.9k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Oncology, 88 papers in Immunology and 27 papers in Molecular Biology. Recurrent topics in James C. Yang's work include Immunotherapy and Immune Responses (78 papers), CAR-T cell therapy research (75 papers) and Cancer Immunotherapy and Biomarkers (41 papers). James C. Yang is often cited by papers focused on Immunotherapy and Immune Responses (78 papers), CAR-T cell therapy research (75 papers) and Cancer Immunotherapy and Biomarkers (41 papers). James C. Yang collaborates with scholars based in United States, Taiwan and South Korea. James C. Yang's co-authors include Steven A. Rosenberg, Nicholas P. Restifo, Mark E. Dudley, Richard A. Morgan, Richard M. Sherry, Carolyn M. Laurençot, Mio Kitano, John R. Wunderlich, Udai S. Kammula and Suzanne L. Topalian and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

James C. Yang

134 papers receiving 20.4k citations

Hit Papers

Cancer immunotherapy: moving beyond current vaccines 1990 2026 2002 2014 2004 2010 2014 2008 2011 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cancer immunotherapy: moving beyond current vaccines
    2004 2.3k citations Steven A. Rosenberg, James C. Yang et al. profile →
  2. Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
    2010 1.9k citations Richard A. Morgan, James C. Yang et al. profile →
  3. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
    2014 1.3k citations Simon Turcotte, Alena Gros et al. profile →
  4. Adoptive cell transfer: a clinical path to effective cancer immunotherapy
    2008 1.2k citations Steven A. Rosenberg, Nicholas P. Restifo et al. profile →
  5. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
    2011 1.1k citations Mark E. Dudley, Steven A. Feldman et al. profile →
  6. A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
    2006 984 citations Sharon Mavroukakis, Donald E. White et al. Clinical Cancer Research profile →
  7. Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
    2010 954 citations Marybeth S. Hughes, Udai S. Kammula et al. Journal of Immunotherapy profile →
  8. Gene Transfer into Humans — Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction
    1990 898 citations Steven A. Rosenberg, Richard A. Morgan et al. profile →
  9. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
    2010 791 citations James C. Yang, Russell C. Langan et al. profile →
  10. Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma
    2002 565 citations Patrick Hwu, Nicholas P. Restifo et al. Journal of Clinical Oncology profile →
  11. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
    2019 301 citations Stephanie L. Goff, James C. Yang et al. Journal of Immunotherapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James C. Yang United States 60 15.3k 12.0k 5.7k 4.1k 2.9k 140 20.9k
Mark E. Dudley United States 58 23.5k 1.5× 20.2k 1.7× 6.8k 1.2× 5.6k 1.4× 2.9k 1.0× 114 29.3k
Richard A. Morgan United States 53 13.3k 0.9× 8.1k 0.7× 7.0k 1.2× 6.5k 1.6× 2.7k 0.9× 124 18.7k
Maryalice Stetler‐Stevenson United States 57 8.9k 0.6× 6.2k 0.5× 4.3k 0.8× 2.3k 0.6× 1.7k 0.6× 230 15.8k
Malcolm K. Brenner United States 98 24.0k 1.6× 13.0k 1.1× 9.2k 1.6× 10.1k 2.5× 4.4k 1.5× 492 35.7k
Paul F. Robbins United States 81 20.3k 1.3× 21.3k 1.8× 8.9k 1.6× 4.1k 1.0× 1.3k 0.5× 179 29.0k
John R. Wunderlich United States 54 15.8k 1.0× 14.8k 1.2× 4.8k 0.8× 3.4k 0.8× 1.2k 0.4× 121 21.1k
Gianpietro Dotti United States 84 19.3k 1.3× 10.4k 0.9× 7.7k 1.3× 6.4k 1.6× 7.8k 2.7× 287 26.5k
Bruce L. Levine United States 76 22.8k 1.5× 13.9k 1.2× 9.2k 1.6× 7.8k 1.9× 5.8k 2.0× 255 32.7k
Michael Kalos United States 39 11.7k 0.8× 6.0k 0.5× 4.9k 0.9× 4.1k 1.0× 2.8k 1.0× 97 15.5k
Renier J. Brentjens United States 59 15.3k 1.0× 6.8k 0.6× 5.2k 0.9× 4.4k 1.1× 4.8k 1.7× 198 18.4k

Countries citing papers authored by James C. Yang

Since Specialization
Citations

This map shows the geographic impact of James C. Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James C. Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James C. Yang more than expected).

Fields of papers citing papers by James C. Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James C. Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James C. Yang. The network helps show where James C. Yang may publish in the future.

Co-authorship network of co-authors of James C. Yang

This figure shows the co-authorship network connecting the top 25 collaborators of James C. Yang. A scholar is included among the top collaborators of James C. Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James C. Yang. James C. Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Coukos, George, Marco Donia, Brian Gastman, et al.. (2025). The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee. Journal for ImmunoTherapy of Cancer. 13(11). e013420–e013420.
2.
3.
Cheng, Ying, Herbert H. Loong, Caicun Zhou, et al.. (2024). Efficacy and safety of 1L selpercatinib in RET fusion-positive NSCLC: LIBRETTO-431 East Asian subgroup analysis.. Journal of Clinical Oncology. 42(23_suppl). 214–214. 1 indexed citations
4.
Sim, Malcolm J. W., Ken‐ichi Hanada, Zhiya Yu, et al.. (2024). Identification and structural characterization of a mutant KRAS‐G12V specific TCR restricted by HLA‐A3. European Journal of Immunology. 54(9). e2451079–e2451079. 1 indexed citations
5.
Kwong, Mei Li M. & James C. Yang. (2024). Lifileucel: FDA-approved T-cell therapy for melanoma. The Oncologist. 29(8). 648–650. 12 indexed citations
6.
Cheng, Ying, James C. Yang, Isamu Okamoto, et al.. (2023). Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia. Immunotherapy. 15(13). 1029–1044. 3 indexed citations
7.
Hecht, J. Randolph, et al.. (2023). Next-Generation Approaches to Immuno-Oncology in GI Cancers. American Society of Clinical Oncology Educational Book. 43(43). e389072–e389072. 1 indexed citations
8.
Hilliard, Jessica, James Kavanaugh, Manuel Schmidt, et al.. (2023). Effect of Dose to the Heart and Cardiac Substructures on Cardiac Toxicity after Breast Cancer Radiation. International Journal of Radiation Oncology*Biology*Physics. 117(2). e180–e180. 1 indexed citations
9.
Wang, Qiong J., et al.. (2016). Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunology Research. 4(3). 204–214. 175 indexed citations
10.
Wang, Qiong J., Zhiya Yu, Ken‐ichi Hanada, et al.. (2016). Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. Clinical Cancer Research. 23(9). 2267–2276. 65 indexed citations
11.
Zhang, Ling, Richard A. Morgan, Joal D. Beane, et al.. (2015). Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma. Clinical Cancer Research. 21(10). 2278–2288. 332 indexed citations
12.
Chandran, Smita S., Biman C. Paria, Abhishek K. Srivastava, et al.. (2014). Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans. Clinical Cancer Research. 21(3). 534–543. 39 indexed citations
13.
Lu, Yong‐Chen, Xin Yao, Jessica S. Crystal, et al.. (2014). Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions. Clinical Cancer Research. 20(13). 3401–3410. 304 indexed citations
14.
Wang, Qiong J., Ken‐ichi Hanada, Paul F. Robbins, Yong F. Li, & James C. Yang. (2012). Distinctive Features of the Differentiated Phenotype and Infiltration of Tumor-Reactive Lymphocytes in Clear Cell Renal Cell Carcinoma. Cancer Research. 72(23). 6119–6129. 55 indexed citations
15.
Tikhonova, Anastasia N., François Van Laethem, Ken‐ichi Hanada, et al.. (2011). αβ T Cell Receptors that Do Not Undergo Major Histocompatibility Complex-Specific Thymic Selection Possess Antibody-like Recognition Specificities. Immunity. 36(1). 79–91. 82 indexed citations
16.
Dudley, Mark E., Colin Gross, Michelle M. Langhan, et al.. (2010). CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma. Clinical Cancer Research. 16(24). 6122–6131. 245 indexed citations
17.
Wang, Qiong J., Ken‐ichi Hanada, & James C. Yang. (2008). Characterization of a Novel Nonclassical T Cell Clone with Broad Reactivity against Human Renal Cell Carcinomas. The Journal of Immunology. 181(6). 3769–3776. 11 indexed citations
18.
Palmer, Douglas C., Sanjeeve Balasubramaniam, Ken‐ichi Hanada, et al.. (2004). Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction. The Journal of Immunology. 173(12). 7209–7216. 97 indexed citations
19.
Phan, Giao Q., Christopher E. Touloukian, James C. Yang, et al.. (2003). Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens. Journal of Immunotherapy. 26(4). 349–356. 91 indexed citations
20.
Wang, Helen Y., Tihui Fu, Gang Wang, et al.. (2002). Induction of CD4+ T cell–dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. Journal of Clinical Investigation. 109(11). 1463–1470. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark E. Dudley Breakdown of academic impact, for papers by Richard A. Morgan Breakdown of academic impact, for papers by Maryalice Stetler‐Stevenson Breakdown of academic impact, for papers by Malcolm K. Brenner Breakdown of academic impact, for papers by Paul F. Robbins Breakdown of academic impact, for papers by John R. Wunderlich Breakdown of academic impact, for papers by Gianpietro Dotti Breakdown of academic impact, for papers by Bruce L. Levine Breakdown of academic impact, for papers by Michael Kalos Breakdown of academic impact, for papers by Renier J. Brentjens
Rankless by CCL
2026